QINGDAO VLAND BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.47 CNY | +10.01% |
|
+33.17% | +21.35% |
| May. 07 | China stocks edge down; HK shares fall after 10-day winning streak | RE |
| Apr. 25 | Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,474 | 4,689 | 3,387 | 3,851 | 4,673 | - | - |
| Enterprise Value (EV) 1 | 3,474 | 4,689 | 3,387 | 3,851 | 4,673 | 4,673 | 4,673 |
| P/E ratio | 22.9 x | 34.4 x | 49.7 x | 47.6 x | 50.6 x | 39 x | 43 x |
| Yield | - | 0.86% | 0.75% | 0.66% | 1.08% | 1.11% | 1.25% |
| Capitalization / Revenue | 3.62 x | 4.07 x | 2.91 x | 3.21 x | 3.62 x | 3.21 x | 3.09 x |
| EV / Revenue | 3.62 x | 4.07 x | 2.91 x | 3.21 x | 3.62 x | 3.21 x | 3.09 x |
| EV / EBITDA | - | - | - | 19.5 x | 19.1 x | 17.1 x | 15.2 x |
| EV / FCF | - | -11.6 x | -13.7 x | - | 26.7 x | 60.7 x | 28.3 x |
| FCF Yield | - | -8.62% | -7.28% | - | 3.74% | 1.65% | 3.53% |
| Price to Book | - | 2.92 x | 2.06 x | 2.25 x | 2.67 x | 2.55 x | 2.52 x |
| Nbr of stocks (in thousands) | 216,534 | 252,085 | 252,412 | 253,029 | 253,029 | - | - |
| Reference price 2 | 16.04 | 18.60 | 13.42 | 15.22 | 18.47 | 18.47 | 18.47 |
| Announcement Date | 4/20/21 | 4/19/22 | 4/26/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 960.2 | 1,151 | 1,163 | 1,199 | 1,290 | 1,457 | 1,511 |
| EBITDA 1 | - | - | - | 197.2 | 245 | 274 | 307 |
| EBIT 1 | - | 170.9 | 102.9 | 122.9 | 139.5 | 173 | 166.5 |
| Operating Margin | - | 14.85% | 8.85% | 10.25% | 10.81% | 11.88% | 11.02% |
| Earnings before Tax (EBT) 1 | - | 171.4 | 102.2 | 122.5 | 139 | 172.7 | 166 |
| Net income 1 | - | 132.6 | 69.84 | 80.71 | 91 | 119.7 | 109 |
| Net margin | - | 11.52% | 6% | 6.73% | 7.05% | 8.22% | 7.21% |
| EPS 2 | 0.7000 | 0.5400 | 0.2700 | 0.3200 | 0.3650 | 0.4733 | 0.4300 |
| Free Cash Flow 1 | - | -404 | -246.6 | - | 175 | 77 | 165 |
| FCF margin | - | -35.1% | -21.2% | - | 13.57% | 5.29% | 10.92% |
| FCF Conversion (EBITDA) | - | - | - | - | 71.43% | 28.1% | 53.75% |
| FCF Conversion (Net income) | - | - | - | - | 192.31% | 64.35% | 151.38% |
| Dividend per Share 2 | - | 0.1600 | 0.1000 | 0.1000 | 0.2000 | 0.2050 | 0.2300 |
| Announcement Date | 4/20/21 | 4/19/22 | 4/26/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -404 | -247 | - | 175 | 77 | 165 |
| ROE (net income / shareholders' equity) | - | 9.42% | 4.3% | 4.82% | 5.24% | 6.27% | 5.86% |
| ROA (Net income/ Total Assets) | - | - | - | - | 2.95% | 2.96% | 3.01% |
| Assets 1 | - | - | - | - | 3,085 | 4,043 | 3,621 |
| Book Value Per Share 2 | - | 6.370 | 6.520 | 6.750 | 6.930 | 7.250 | 7.330 |
| Cash Flow per Share 2 | - | - | 0.3800 | 0.6100 | 0.7600 | 0.9000 | 1.010 |
| Capex 1 | - | 493 | 342 | 215 | 256 | 208 | 251 |
| Capex / Sales | - | 42.88% | 29.4% | 17.91% | 19.81% | 14.3% | 16.58% |
| Announcement Date | 4/20/21 | 4/19/22 | 4/26/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
18.47
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.35% | 647M | |
| +2.93% | 108B | |
| -5.15% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- 603739 Stock
- Financials Qingdao Vland Biotech INC.